Browsing by Author "Vidal-Puig, Antonio"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Adaptive changes of the Insig1/SREBP1/SCD1 set point help adipose tissue to cope with increased storage demands of obesity
    (American Diabetes Association, 2013-11) Carobbio, Stefania; Hagen, Rachel M.; Lelliott, Christopher J.; Slawik, Marc; Medina-Gomez, Gema; Tan, Chong-Yew; Sicard, Audrey; Atherton, Helen J.; Barbarroja, Nuria; Bjursell, Mikael; Bohlooly-Y, Mohammad; Virtue, Sam; Tuthill, Antoinette; Lefai, Etienne; Laville, Martine; Wu, Tingting; Considine, Robert V.; Vidal, Hubert; Langin, Dominique; Oresic, Matej; Tinahones, Francisco J.; Manuel Fernandez-Real, Jose; Griffin, Julian L.; Sethi, Jaswinder K.; López, Miguel; Vidal-Puig, Antonio; Medicine, School of Medicine
    The epidemic of obesity imposes unprecedented challenges on human adipose tissue (WAT) storage capacity that may benefit from adaptive mechanisms to maintain adipocyte functionality. Here, we demonstrate that changes in the regulatory feedback set point control of Insig1/SREBP1 represent an adaptive response that preserves WAT lipid homeostasis in obese and insulin-resistant states. In our experiments, we show that Insig1 mRNA expression decreases in WAT from mice with obesity-associated insulin resistance and from morbidly obese humans and in in vitro models of adipocyte insulin resistance. Insig1 downregulation is part of an adaptive response that promotes the maintenance of SREBP1 maturation and facilitates lipogenesis and availability of appropriate levels of fatty acid unsaturation, partially compensating the antilipogenic effect associated with insulin resistance. We describe for the first time the existence of this adaptive mechanism in WAT, which involves Insig1/SREBP1 and preserves the degree of lipid unsaturation under conditions of obesity-induced insulin resistance. These adaptive mechanisms contribute to maintain lipid desaturation through preferential SCD1 regulation and facilitate fat storage in WAT, despite on-going metabolic stress.
  • Thumbnail Image
    Item
    Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation
    (PNAS, 2015-01-13) Patel, Meghana N.; Bernard, William G.; Milev, Nikolay B.; Cawthorn, William P.; Figg, Nichola; Hart, Dan; Prieur, Xavier; Virtue, Sam; Hegyi, Krisztina; Bonnafous, Stephanie; Bailly-Maitre, Beatrice; Chu, Yajing; Griffin, Julian L.; Mallat, Ziad; Considine, Robert V.; Tran, Albert; Gual, Philippe; Takeuchi, Osamu; Akira, Shizuo; Vidal-Puig, Antonio; Bennett, Martin R.; Sethi, Jaswinder K.; Department of Medicine, IU School of Medicine
    Obesity increases the risk of developing life-threatening metabolic diseases including cardiovascular disease, fatty liver disease, diabetes, and cancer. Efforts to curb the global obesity epidemic and its impact have proven unsuccessful in part by a limited understanding of these chronic progressive diseases. It is clear that low-grade chronic inflammation, or metaflammation, underlies the pathogenesis of obesity-associated type 2 diabetes and atherosclerosis. However, the mechanisms that maintain chronicity and prevent inflammatory resolution are poorly understood. Here, we show that inhibitor of κB kinase epsilon (IKBKE) is a novel regulator that limits chronic inflammation during metabolic disease and atherosclerosis. The pathogenic relevance of IKBKE was indicated by the colocalization with macrophages in human and murine tissues and in atherosclerotic plaques. Genetic ablation of IKBKE resulted in enhanced and prolonged priming of the NLRP3 inflammasome in cultured macrophages, in hypertrophic adipose tissue, and in livers of hypercholesterolemic mice. This altered profile associated with enhanced acute phase response, deregulated cholesterol metabolism, and steatoheptatitis. Restoring IKBKE only in hematopoietic cells was sufficient to reverse elevated inflammasome priming and these metabolic features. In advanced atherosclerotic plaques, loss of IKBKE and hematopoietic cell restoration altered plaque composition. These studies reveal a new role for hematopoietic IKBKE: to limit inflammasome priming and metaflammation.
  • Thumbnail Image
    Item
    A Prevalent Variant in PPP1R3A Impairs Glycogen Synthesis and Reduces Muscle Glycogen Content in Humans and Mice
    (PLOS, 2008-01-29) Savage, David B.; Zha, Lanmin; Ravikumar, Balasubramanian; Choi, Cheol Soo; Snaar, Johanna E.; McGuire, Amanda C.; Wou, Sung-Eun; Medina-Gomez, Gemma; Kim, Sheene; Bock, Cheryl B.; Segvich, Dyann M.; Vidal-Puig, Antonio; Wareham, Nicholas J.; Shulman, Gerald I.; Karpe, Fredrik; Taylor, Roy; Pederson, Bartholomew A.; Roach, Peter J.; O’Rahilly, Stephen; DePaoli-Roach, Anna A.; Biochemistry and Molecular Biology, School of Medicine
    Background Stored glycogen is an important source of energy for skeletal muscle. Human genetic disorders primarily affecting skeletal muscle glycogen turnover are well-recognised, but rare. We previously reported that a frameshift/premature stop mutation in PPP1R3A, the gene encoding RGL, a key regulator of muscle glycogen metabolism, was present in 1.36% of participants from a population of white individuals in the UK. However, the functional implications of the mutation were not known. The objective of this study was to characterise the molecular and physiological consequences of this genetic variant. Methods and Findings In this study we found a similar prevalence of the variant in an independent UK white population of 744 participants (1.46%) and, using in vivo 13C magnetic resonance spectroscopy studies, demonstrate that human carriers (n = 6) of the variant have low basal (65% lower, p = 0.002) and postprandial muscle glycogen levels. Mice engineered to express the equivalent mutation had similarly decreased muscle glycogen levels (40% lower in heterozygous knock-in mice, p < 0.05). In muscle tissue from these mice, failure of the truncated mutant to bind glycogen and colocalize with glycogen synthase (GS) decreased GS and increased glycogen phosphorylase activity states, which account for the decreased glycogen content. Conclusions Thus, PPP1R3A C1984ΔAG (stop codon 668) is, to our knowledge, the first prevalent mutation described that directly impairs glycogen synthesis and decreases glycogen levels in human skeletal muscle. The fact that it is present in ∼1 in 70 UK whites increases the potential biomedical relevance of these observations.
  • Thumbnail Image
    Item
    Role of the POZ zinc finger transcription factor FBI-1 in human and murine adipogenesis.
    (ASBMB, 2004-03-19) Laudes, Matthias; Christodoulides, Constantinos; Sewter, Ciaran; Rochford, Justin J.; Considine, Robert V.; Sethi, Jaswinder K.; Vidal-Puig, Antonio; O’Rahilly, Stephen; Department of Medicine, IU School of Medicine
    Poxvirus zinc finger (POZ) zinc finger domain transcription factors have been shown to play a role in the control of growth arrest and differentiation in several types of mesenchymal cells but not, as yet, adipocytes. We found that a POZ domain protein, factor that binds to inducer of short transcripts-1 (FBI-1), was induced during both murine and human preadipocyte differentiation with maximal expression levels seen at days 2-4. FBI-1 mRNA was expressed in human adipose tissue with the highest levels found in samples from morbidly obese subjects. Murine cell lines constitutively expressing FBI-1 showed evidence for accelerated adipogenesis with earlier induction of markers of differentiation and enhanced lipid accumulation, suggesting that FBI-1 may be an active participant in the differentiation process. Consistent with the properties of this family of proteins in other cell systems, 3T3L1 cells stably overexpressing FBI-1 showed reduced DNA synthesis and reduced expression of cyclin A, cyclin-dependent kinase 2, and p107, proteins known to be involved in the regulation of mitotic clonal expansion. In addition, FBI-1 reduced the transcriptional activity of the cyclin A promoter. Thus, FBI-1, a POZ zinc finger transcription factor, is induced during the early phases of human and murine preadipocyte differentiation where it may contribute to adipogenesis through influencing the switch from cellular proliferation to terminal differentiation.